{"id":"W3081787367","doi":"10.1158/1538-7445.am2020-ct221","title":"Abstract CT221: Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment for patients with advanced non-small cell lung cancer (NSCLC) with brain metastases: Results from CheckMate 227","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Cancer Foundation","funders":"","keywords":"Medicine; Internal medicine; Nivolumab; Ipilimumab; Oncology; Lung cancer; Brain metastasis; Asymptomatic; Cancer; Performance status; Gastroenterology; Immunotherapy; Metastasis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004059852,0.00066263,0.0009990649,0.0001963247,0.0004219949,0.0001111375,0.000329657,0.0001449102,0.0007021235],"category_scores_gemma":[0.0001857991,0.0004413119,0.000231711,0.000715672,0.0002159159,0.0002214684,0.0001133416,0.0005109939,0.00006247461],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001380824,"about_ca_system_score_gemma":0.001727032,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0122662,"about_ca_topic_score_gemma":0.004258005,"domain_scores_codex":[0.995285,0.0001104548,0.0006304079,0.001512627,0.001207717,0.00125376],"domain_scores_gemma":[0.9963461,0.0007446871,0.000286859,0.0009157219,0.0009044239,0.0008022214],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5037864,0.01909098,0.07169019,0.007419538,0.01517615,0.003143037,0.01776667,0.0140837,0.01255073,0.0000886258,0.06797941,0.2672245],"study_design_scores_gemma":[0.4797234,0.07395796,0.08058051,0.007204734,0.005052799,0.00001594289,0.003378239,0.004553464,0.1326512,0.0001213837,0.20927,0.003490383],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9725348,0.003502197,0.0001910265,0.009488414,0.0001247434,0.006356758,0.006984212,0.0001022538,0.0007155783],"genre_scores_gemma":[0.9871657,0.001474662,0.003082487,0.0008871696,0.0005386383,0.003398325,0.002076817,0.0002073962,0.001168819],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2637341,"threshold_uncertainty_score":0.9998038,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05385758993707476,"score_gpt":0.3624827389685978,"score_spread":0.308625149031523,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}